Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Daratumumab maintenance therapy with or without pomalidomide provided a tolerable and feasible treatment option after salvage hematopoietic stem cell transplantation in patients with relapsed multiple myeloma.
Maintenance Darzalex, with or without Pomalyst was safe and efficacious in treating patients with relapsed myeloma who underwent salvage autologous hematopoietic stem cell transplant.
Teclistamab continued to elicit deep and durable responses in patients with relapsed/refractory multiple myeloma, irrespective of being triple-class refractory, daratumumab-refractory, or refractory to last line of therapy.
NEW YORK, NY. (PRWEB) June 06, 2023 -- Dr. Steven Victor received his Bachelor of Arts degree from New York University School of Arts and Sciences, followed
-- In CIBMTR Registry Analysis, Tecartus Also Demonstrates 88% Complete Response Rate and 94% Overall Response Rate in Second-and-Third-Line Treatment -- -- Data Highlighted in Oral Presentation at... | June 6, 2023